Similar Posts
Why Are Investors Running Away from Medical Devices?
Sabin Russell wrote a great piece in Health Affairs recently, on the drought in investment to develop new medical devices. Read it if you have access. If you don’t, here are some of her main points. 1. Venture capital for device manufacturers has been drying up for a while: “‘For five years, this industry has…
Are Medicare Prescription Benefits Too Stingy?
The bill she received in the mail revealed a staggering figure — $9,225 for one infusion of Avastin, a chemotherapy drug. And she would need many more such infusions. Fortunately, the dollar amount is what medical experts call a “charge,” which in normal marketplaces refers to the amount a provider expects for the good or…
Rare Diseases Are Becoming Too Common. Sound Impossible? Here's Why It's Not
It is hard to make money treating rare diseases. There simply aren’t enough customers to generate many profits. That’s why the U.S. government passed the Orphan Drug Act in 1983, a law which created a series of incentives to encourage drug companies to develop treatments for rare or “orphan” diseases – conditions affecting less than…
A Drug to Treat Cancer and Heart Disease (Miracle Cure or Media Hype?)
In a recent New York Times article, physician-author Siddhartha Mukherjee wrote about a clinical trial that he characterized as “beautiful,” for potentially illuminating a surprising connection between heart disease and cancer. Mukherjee is a justifiably acclaimed writer, who publishes regularly in The New Yorkerand The New York Times, and who won a Pulitzer for his bestselling book The Emperor of All Maladies. But…
Copay Assistance Controversy Continues
My article with Peter Bach of Memorial Sloan Kettering continues to generate debate. The two of us argues that copay assistance programs from pharmaceutical companies help specific patients in the short run, but make it easier for drug companies to demand high prices for their products. Here is one take on the topic, spurred on…
Puccini Was Dying Of Cancer—Hiding His Diagnosis Was A Grave Mistake
It would have been a difficult ending under the best of circumstances. Composing what would be his last opera, Giacomo Puccini was struggling to humanize Turandot, daughter of the Emperor and a woman of mesmerizing beauty. Early in the opera, she had cruelly disposed of a series of want-to-be suitors, beheading some and torturing others,…